Number (%) of 720 patients in the ESPOIR early arthritis cohort who were in remission according to each of 7 criteria, and number (%) who were in remission and had residual abnormalities of specific measures or joints.
| N (% of all pts) | Boolean 93 (12.9) | SDAI ≤ 3.3 123 (17.1) | DAS28 ≤ 2.6 234 (32.5) | CDAI ≤ 2.8 129 (17.9) | RAPID3R ≤ 3 181 (25.1) | RAPID3R + SJ1 131 (18.2) | RAPID3 +SJ1+D1 112 (15.6) |
|---|---|---|---|---|---|---|---|
| Measure: no. (%) patients in remission by each description with residual symptoms | |||||||
| TJC28 > 1 | 0 (0) | 4 (3) | 26 (11) | 4 (3) | 46 (24) | 22 (16) | 18 (15) |
| SJC28 > 1 | 0 (0) | 3 (2) | 38 (16) | 3 (2) | 53 (27) | 0 (0) | 0 (0) |
| CRP > 1 | 0 (0) | 4 (3) | 14 (6) | 10 (7) | 14 (8) | 8 (6) | 7 (6) |
| DOCGL > 1 | 7 (7) | 10 (8) | 90 (37) | 11 (8) | 44 (23) | 20 (14) | 0 (0) |
| PATGL > 1 | 0 (0) | 24 (19) | 117 (49) | 29 (21) | 40 (21) | 25 (18) | 13 (11) |
| Pain > 1 | 15 (16) | 29 (23) | 100 (46) | 29 (21) | 33 (17) | 19 (13) | 14 (12) |
| HAQ-FN > 0.5 | 5 (5) | 12 (9) | 29 (12) | 13 (9) | 3 (1) | 3 (2) | 3 (2) |
| Swollen joint counts: no. (%) patients in remission by each description with residual swollen joints | |||||||
| Knees ≥ 1 | 0 (0) | 0 (0) | 7 (3) | 1 (1) | 9 (4) | 2 (1.5) | 1 (1) |
| Shoulders ≥ 1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Elbows ≥ 1 | 0 (0) | 0 (0) | 5 (2) | 0 (0) | 2 (1) | 0 (0) | 0 (0) |
| Wrists ≥ 1 | 5 (5) | 5 (4) | 19 (8) | 5 (4) | 22 (11) | 6 (4) | 6 (5) |
| MCP ≥ 1 | 9 (9) | 11 (9) | 46 (21) | 10 (7) | 52 (27) | 13 (9) | 10 (8) |
| PIP ≥ 1 | 3 (3) | 5 (5) | 24 (11) | 5 (4) | 14 (19) | 4 (3) | 4 (3) |
CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity index; DAS28: Disease Activity Score-28; RAPID3: Routine Assessment of Patient Index Data; TJC: tender joint count; SJC: swollen joint count; CRP: C-reactive protein; PATGL: patient global estimate; DOCGL: physician global estimate; HAQ-FN: Health Assessment Questionnaire-Function; MCP: metacarpophalangeal; PIP: proximal interphalangeal.